Medistim posts record quarter, introduces quarterly dividend

Spago Nanomedical’s Board of Directors has resolved to apply for delisting from the Nasdaq First North Growth Market, subject to approval at an extraordinary general meeting on November 19, 2026. The goal is to make it easier to finance the next phase of Tumorad’s development with long-term specialist investors.

Swedish medtech company Getinge raised its adjusted EBITA margin to 15.1% in the third quarter of 2026, from 13.1% a year earlier, while organic sales grew 2.1%. The company kept its forecast of 3–5% organic sales growth for the full year.

UK digital pathology provider Diagnexia has signed an agreement to use Swedish medical imaging IT company Sectra’s cloud-based Image Exchange Portal to receive, send and report on pathology cases from NHS organizations.

SciBase has secured its first positive US medical policy from a major Blue Cross Blue Shield organization: Highmark will cover the company's Nevisense skin lesion assessment for patients being evaluated for possible melanoma.

Swedish medtech company NanoEcho has been declared bankrupt after failing to find a solution to its strained financial situation.

Stockholm-based healthtech company Encare has signed an agreement with the National Cancer Institute of Thailand (NCI Thailand) to support the implementation of Enhanced Recovery After Surgery (ERAS) in colorectal surgery. The Bangkok institute, which operates under Thailand’s Ministry of Public Health, is Encare’s first hospital partner in the country.

Oncopeptides has raised SEK 100 million before costs in a directed share issue to Swedish and international institutional investors. The money will fund the next clinical development phase of its glioblastoma program.